Hematopoietic and Lymphoid System Neoplasm

Diseases /

Hematopoietic and Lymphoid System Neoplasm

Back to Diseases List

Associated Genetic Biomarkers

AKT1
AKT1 Amplification
AKT1 Mutation
AKT2
AKT2 Amplification
AKT2 Mutation
AKT3
AKT3 Amplification
AKT3 Mutation
CRKL
CRKL Mutation
MTOR
MTOR Mutation
PDGFRA
PDGFRA Amplification
PDGFRA Mutation
PIK3CA
PIK3CA Amplification
PIK3CA Mutation
PIK3CG

PIK3CG Mutation
PIK3R1
PIK3R1 Mutation
PIK3R2
PIK3R2 Mutation
PTEN
PTEN Deficient Expression
PTEN Loss
PTEN Mutation
RICTOR

RICTOR Amplification
RICTOR Mutation
RPTOR
RPTOR Mutation
TNFRSF8 Expression
TSC1
TSC1 Mutation
TSC2
TSC2 Mutation

Overview

NCI Definition: Neoplasms of the hematopoietic system, including hematopoietic cell neoplasms (e.g. leukemias, lymphomas) and non-hematopoietic cell neoplasms that can affect the hematopoietic system (e.g. lymph node and splenic sarcomas). --2003 [1]

Clinical Trials

View Clinical Trials for Hematopoietic and Lymphoid System Neoplasm

There are 3 clinical trials for hematopoietic and lymphoid system neoplasm, of which 3 are open and 0 are completed or closed. Of the trials that contain hematopoietic and lymphoid system neoplasm as an inclusion criterion, 2 are phase 1 (2 open) and 1 is phase 1/phase 2 (1 open).

AKT1, AKT2, and AKT3 are the most frequent gene inclusion criteria for hematopoietic and lymphoid system neoplasm clinical trials [3].

Trials Investigating Hematopoietic And Lymphoid System Neoplasm by Gene and Recruiting Status

Avapritinib, brentuximab vedotin, and cyclophosphamide are the most common interventions in hematopoietic and lymphoid system neoplasm clinical trials.

Drugs Being Investigated in Hematopoietic And Lymphoid System Neoplasm Trials by Recruiting Status

Significant Genes in Hematopoietic and Lymphoid System Neoplasm

AKT1 +

AKT1 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT1 status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

AKT2 +

AKT2 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT2 status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

AKT3 +

AKT3 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains AKT3 status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

CRKL +

CRKL is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains CRKL status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

MTOR +

MTOR is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains MTOR status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PDGFRA +

PDGFRA is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PDGFRA status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3CA +

PIK3CA is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3CA status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3CG +

PIK3CG is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3CG status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3R1 +

PIK3R1 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3R1 status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PIK3R2 +

PIK3R2 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PIK3R2 status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

PTEN +

PTEN is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains PTEN status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

RICTOR +

RICTOR is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RICTOR status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

RPTOR +

RPTOR is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains RPTOR status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

TSC1 +

TSC1 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TSC1 status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

TSC2 +

TSC2 is an inclusion eligibility criterion in 1 clinical trial for hematopoietic and lymphoid system neoplasm, of which 1 is open and 0 are closed. Of the trial that contains TSC2 status and hematopoietic and lymphoid system neoplasm as inclusion criteria, 1 is phase 1 (1 open) [3].

Disease Details

Parent(s)

Neoplasm

Children

Bone Marrow Neoplasm, Hematopoietic and Lymphoid Cell Neoplasm, Hematopoietic and Lymphoid Malignancy, Splenic Neoplasm, and Lymph Node Neoplasm

References

1. National Cancer Institute. NCI Thesaurus Version 18.11d. https://ncit.nci.nih.gov/ncitbrowser/ [2018-08-28]. [2018-09-21].

2. The AACR Project GENIE Consortium. AACR Project GENIE: powering precision medicine through an international consortium. Cancer Discovery. 2017;7(8):818-831. Dataset Version 8. This dataset does not represent the totality of the genetic landscape; see paper for more information.

3. All assertions and clinical trial landscape data are curated from primary sources. You can read more about the curation process here.

Diseases /

Hematopoietic and Lymphoid System Neoplasm

Back to Diseases List

Associated Genetic Biomarkers

Overview

Clinical Trials

Significant Genes in Hematopoietic and Lymphoid System Neoplasm

Disease Details

References

About

Molecular Medicine

Content Types